ASH 2024: Updates in the Treatment of CLL - Episode 14

Emerging Data on BTK Inhibitor Degraders and Bispecifics in R/R CLL: Updated Results at ASH 2024

Panelists discuss how novel Bruton tyrosine kinase (BTK) degraders like NX-5948 and BGB-16673 are showing promising early clinical activity in relapsed/refractory chronic lymphocytic leukemia (R/R CLL) based on ASH 2024 data, while bispecific antibodies such as epcoritamab from the EPCORE CLL-1 trial represent another emerging therapeutic approach, though longer follow-up is needed to fully understand their optimal role in the treatment landscape.

EP. 1: Expert Insights in Selecting Frontline Therapies in TN CLL: Fixed-Duration Venetoclax vs Continuous BTKi
EP. 2: ASH 2024 Updates: SEQUOIA 5-Year Follow-Up and Expert Perspectives in Selecting Between Acalabrutinib vs Zanubrutinib in TN CLL
EP. 3: Real-World Observations: Firstline cBTKi Switches and Cardiac AEs in TN CLL
EP. 4: Clinical Insights: Exploring Combination Regimens in First-Line Treatment in CLL: SEQUOIA Arm D and BOVen Trials
EP. 5: Key Takeaways From the AMPLIFY Trial at ASH 2024: Fixed-Duration Acalabrutinib Plus Venetoclax With or Without Obinutuzumab vs Chemoimmunotherapy in TN CLL
EP. 6: ASH 2024 Updates: Evaluating Potential Frontline Triplet Regimen: Pirtobrutinib Plus Venetoclax Plus Obinutuzumab in TN CLL
EP. 7: Expert Perspectives: Navigating the Emerging Treatment Landscape of Combination Therapies in TN CLL—Applying Evidence to Clinical Practice
EP. 8: Expert Insights: Treatment Selection in Second-Line R/R CLL and Limitations of Applying MAIC Data in the Real-World Practice Setting
EP. 9: ASH 2024 Highlights: Phase 2 Study of Zanubrutinib Plus Venetoclax in R/R CLL
EP. 10: Treatment Sequencing in R/R CLL: Optimizing Strategies and Clinical Insights From ASH 2024 Real-World Data
EP. 11: Pirtobrutinib in R/R CLL: Can It Be Used in the Second-Line Setting?
EP. 12: Sequencing Treatment in R/R CLL: CAR T-Cell Therapy vs Pirtobrutinib in Double-Exposed Patients
EP. 13: Real-World Observations With Pirtobrutinib and New Data From the BRUIN CLL-321 Trial at ASH 2024
Now Viewing
EP. 14: Emerging Data on BTK Inhibitor Degraders and Bispecifics in R/R CLL: Updated Results at ASH 2024

Video content above is prompted by the following:

  • There’s been a lot of emerging data with the BTK degraders in R/R CLL. Dr Kahl, what are your perspectives/insights on novel agents like NX-5948?
  • What are your thoughts on agents like BGB-16673?
  • Another exciting class is bispecifics in R/R CLL. Can you share the updated results with epcoritamab from the EPCORE CLL-1 trial?

Related Content:

ASH 2024: Updates in the Treatment of CLL Video SeriesOncLive Peer Exchange®
Real-World Data in Myelofibrosis: Bridging the Gap Between Clinical Trials and Practice
Advancing Myelofibrosis Treatment: Personalized Strategies with Fedratinib and Ruxolitinib
Key Updates in the Treatment of ES-SCLC